Risk of using hydroxychloroquine as a treatment of COVID-19

Int J Risk Saf Med. 2020;31(3):111-116. doi: 10.3233/JRS-200024.

Abstract

The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting conditions, administering such a drug could be fatal, particularly when taken at high doses or in combination with other antibiotics. However, further well-designed studies that would address the optimal dose, duration of treatment, possible side effects, and long-term usage outcomes are needed to make the final decision. In this paper, we aim to discuss the risk of using HCQ in treating COVID-19 patients, including its possible side effects.

Keywords: COVID-19; Hydroxychloroquine.

MeSH terms

  • Antimalarials / adverse effects
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / pharmacology
  • Hydroxychloroquine / therapeutic use*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2

Substances

  • Antimalarials
  • Hydroxychloroquine